ProMetic Life Sciences Q3 2016 Earnings Presentation

ProMetic Life Sciences presented Q3 2016 results and strategic updates on its biopharmaceutical pipeline spanning small molecule drugs and plasma protein therapies. The presentation outlines the company's clinical programs including Plasminogen, IVIG, and PBI-4050, alongside financial performance and cash runway analysis as it gears toward the commercial phase.